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• Subjects 
Sixty-seven children ( 3 years of age) with SCA were categorised according to their degree of cerebral 
vasculopathy evaluated by transcranial Doppler velocities and magnetic resonance imaging:  Stroke group, 
included  15 SCA children with history of at least one stroke episode; Risk group, included  32 SCA children 
with high transcranial Doppler (TCD) velocities, either “conditional” (170 – 199 cm/s) or “high risk” (>200 
cm/s), and children with silent infarcts or cerebral vasculopathy on magnetic resonance imaging (MRI); 
Control  group, included 20 SCA children without previous history of stroke, normal TCD velocities and no 
abnormalities on MRI.   
• Hematological and imaging data were retrospectively obtained from patients’ medical records at 
Greater Lisbon area hospitals.  
• Genotyping of six known SNPs was performed using PCR-RFLP or Sanger sequencing: HGB2: rs7482144; 
HBS1L-MYB: rs4895441, rs9399137 and rs9389268; and BCL11A: rs11886868 and rs4671393. KLF1  gene 
and its promoter region  (total of 3.2 kb) were analysed using Next-Generation Sequencing – Nextera XT  
methodology,  in a MiSeq equipment, Illumina. Data analyses were performed using MiSeq reporter v2.6.2 
and Integrative Genomics Viewer v2.3.86. 
• Statistical analyses were performed with  SPSS v23. Median and 95% CI were used to describe 
hematological parameters of patients in each group. Differences  in the median values of HbF was 
analysed by the Mann-Whitney or Kruskal-Wallis  non-parametric tests.   A p value of < 0.05 was 
considered statistical significant. 
• In silico studies  of the novel variant  in KLF1 were done using PolyPhen-2.  
Our results corroborate previous studies suggesting that a low level of HbF in SCA patients is a risk factor for stroke (6).  
The results from this study confirm that KLF1 is an essential modulator of HbF expression in SCA. We report for the first time the importance of KLF1 variants in 
combination with other genetic modifiers (namely HBG2, BCL11A and HBS1L-MYB) to the final phenotypic expression of HbF in SCA children with different degrees 
of cerebral vasculopathy. Consequently, this study allowed the delineation of a genetic pattern with prognostic value for SCA.  
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Fig. 1. Fetal to adult hemoglobin switching.  
a. Timing of β-like globin subunit switching during human ontogeny. 
The embryonic, fetal and adult stages are shown in blue, green and 
red, respectively. b. Regulators of hemoglobin switching including 
KLF1, BCL11A, and MYB. Gene activation is depicted with an arrow, 
and gene repression with a blunt-ended arrow.  BCL11A binding 
sites are indicated with an asterisk (*). LCR=Locus control region; 
HSs= DNase hypersensitive sites. 
Sickle Cell Anemia (SCA) is a hereditary anemia caused by homozygosity for the c.20A>T mutation in the beta-globin gene (HBB) 
that  gives rise to hemoglobin S (HbS). In low-oxygenated blood, HbS molecules form polymers which stretch and deform the red 
blood cells and dramatically alter their mechanical and rheological properties, leading to recurrent episodes of vaso-occlusion and 
chronic hemolysis. 
Cerebral vasculopathy is one of the most devastating complications of this disease and even young children with SCA have a high 
risk of stroke. It occurs in about 11% of these children before the age of 20 (1, 2).  Pathophysiology of stroke is complex and the 
underlying mechanisms remain largely unknown (3).  
Some environmental and genetic determinants are able to modulate the onset, course and outcome of the SCA. Among those, the 
level of fetal hemoglobin (HbF; α2γ2) has been proposed as the most significant disease modulator (4, 5). HbF is the major form of 
Hb expression during gestation. Around birth, fetal to adult hemoglobin switching occurs gradually (Fig. 1a) being regulated by 
transcription factors, including BCL11A, MYB, and KLF1 (Fig. 1b).  
In this work, we aimed to investigate if the level of HbF in SCA children is related with their risk of stroke and if their level of HbF is 
modulated by variants in genes, such as HBG2, BCL11A, HBS1L-MYB, and KLF1.  
 
Adapted from Sankaran and Weiss, 2015 [5]  
All the sixty-seven children analysed presented homozygosity for the c.20A>T mutation in 
the HBB gene, confirming they are SCA patients.  
                                                                However, these SCA children presented a variable                                                 
                                                                level of HbF (median 9.3%; min 1.5; max 27.8).  
           When they were grouped according to their degree              
                                                                of cerebral vasculopathy (Fig. 2), it was observed that      
                                                                lower HbF levels are associated with stroke events          
                                                                 (p=0.005).  
 
 
 
 
II.3 - We further examined the effect of  the co-
inheritance of KLF1 variants and the other SNPs in 
HBG2, BCL11A and HBS1L-MYB. These include the T 
alele at HBG2 rs7482144, the A allele at BCL11A 
rs46671393, the G allele at HBS1L-MYB rs4895441 and 
the C allele at HBS1L-MYB rs9399137. 
The wide range of HbF expression observed among the 
SCA patients pointed to a combined effect of KLF1 
variants and the other genetic modifier factors. In Fig. 5 
is demonstrated the additive effect of these genetic 
modifiers for higher expression of HbF in SCA (p=0.021). 
 
 
 
 
 
 
                                                                                               
 
 
 
 
  
 
 
                                
                                     II.2 – The spectrum of variants in KLF1 gene 
Eleven distinct variants were identified by NGS and validated by Sanger sequencing (Fig. 
4a and b) in the analysed SCA children.  We have found one novel missense variant, 
c.1026G>C, located at exon 3.  However, in silico studies have predicted a benign 
consequence at protein level [p.Q342H]: HumDiv score = 0.013; HumVar score = 0.063 
(Fig.  4c).  
The majority of these SCA patients  (83%)  presented at least one variant in KLF1 gene. 
 
  
Fig. 4a. Schematic illustration of KLF1 gene with the identification of the eleven distint variants found. 
EI, EII and EIII indicate exons 1, 2 and 3, respectively. F1, F2 and F3 depict the three zinc finger domains.  
b. DNA sequencing profile of the novel variant c.1026G>C found in heterozygosity in one patient.  
c. In silico analysis of the novel variant using the Polyphen-2 sofware. 
Prediction/Confidence   PolyPhen-2 v2.2.2r398 
HumDiv 
This mutation is predicted to be BE NIG N  with a score of 0.013 (sensitivity: 0.96; specificity: 0.78) 
 
HumVar 
This mutation is predicted to be BE NIG N  with a score of 0.063 (sensitivity: 0.92; specificity: 0.65) 
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Fig.  2. Box plots showing HbF levels presented by SCA patients  
according to their degree of cerebral vasculopathy (Control; Risk; Stroke). 
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Fig.  3. Box plots  showing HbF levels presented by 
SCA patients  according to their  genotype at HBG2, 
rs7482144. 
II - Genetic modulation of fetal hemoglobin phenotypic expression  
I - Fetal hemoglobin level and risk of stroke in SCA 
Fig. 5. Box plots showing the HbF levels presented by 
SCA patients (-) without variants in KLF1, HBG2, MYB 
and BCL11A; and (+) presenting at least one variant in 
KLF1 and the set of HBG2 rs7482144_T allele, BCL11A 
rs46671393_A allele, HBS1L-MYB rs4895441_G allele 
and HBS1L-MYB rs9399137_C allele. 
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CONCLUSIONS 
 
II.1 – SNPs in genes, such as HBG2, BCL11A 
and HBS1L-MYB, may modulate the 
phenotypic expression of HbF in SCA.  For 
example (Fig. 3), we have observed that SCA 
patients with the rarest genotypes in HBG2 
(rs7482144_TT+TC) presented higher levels 
of HbF (p=0.031).  
Additionally, the rs11886868_C and the 
rs4671393_A alleles in BCL11A also seemed 
to predispose to higher HbF levels. 
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